Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ES 009

Next Previous
Search
Drug Profile

ES 009

Alternative Names: ES-009

Latest Information Update: 27 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elpiscience Biopharmaceuticals
  • Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action LILRB2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 07 Sep 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in Australia (IV) (NCT06007482)
  • 16 Aug 2023 Elpiscience Biopharma plans a phase I trial for Solid tumours (Late stage disease, Metastatic disease, Unresectable/Inoperable, Second line therapy or greater, Monotherapy) in Australia (IV, Infusion) in August 2023 (NCT06007482)
  • 20 Nov 2022 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 37th Annual meeting of Society for Immunotherapy of Cancer’s (SITC-2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top